Stockscreener 앱 받기
26.80
4.56%
1.17
시간 외 거래:
26.80
전일 마감가:
$25.63
열려 있는:
$25.63
하루 거래량:
1.40M
Relative Volume:
0.50
시가총액:
$3.34B
수익:
$22.12M
순이익/손실:
$-245.15M
주가수익비율:
-6.9527
EPS:
-3.8546
순현금흐름:
$-373.40M
1주 성능:
+1.75%
1개월 성능:
+27.07%
6개월 성능:
+500.90%
1년 성능:
+432.80%
1일 변동 폭
$24.80
$27.79
1주일 범위
$24.80
$27.79
52주 변동 폭
$2.7601
$28.29
Alumis Inc Stock (ALMS) Company Profile
명칭
Alumis Inc
전화
650-231-6625
주소
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
26.80 | 3.20B | 22.12M | -245.15M | -373.40M | -3.8546 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-21 | 개시 | Chardan Capital Markets | Buy |
| 2025-07-25 | 개시 | Wells Fargo | Overweight |
| 2025-06-10 | 재개 | Guggenheim | Buy |
| 2025-01-30 | 개시 | Oppenheimer | Outperform |
| 2024-10-31 | 개시 | Robert W. Baird | Outperform |
| 2024-10-17 | 개시 | H.C. Wainwright | Buy |
| 2024-07-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-23 | 개시 | Guggenheim | Buy |
| 2024-07-23 | 개시 | Leerink Partners | Outperform |
| 2024-07-23 | 개시 | Morgan Stanley | Overweight |
모두보기
Alumis Inc 주식(ALMS)의 최신 뉴스
Alumis Highlights Phase III Psoriasis Wins, NDA Timing, and Lupus Catalyst at Guggenheim Summit - Yahoo Finance
Quarterly Risk: Is Alumis Inc in a consolidation phase2025 Price Action Summary & Growth Focused Entry Reports - baoquankhu1.vn
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. - AOL.com
Stop Loss: Is Alumis Inc gaining market shareJuly 2025 WrapUp & Daily Profit Focused Screening - baoquankhu1.vn
Alumis (ALMS) Valuation Check After Strong Multi‑Month Share Price Momentum - Yahoo Finance
EPS Watch: Can Alumis Inc ride the EV waveWeekly Stock Analysis & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Market Leaders: Will TWFG outperform the market in YEARTrade Analysis Report & High Win Rate Trade Alerts - baoquankhu1.vn
Alumis Ownership Shifts As Shelf Filing And Conferences Shape Outlook - Sahm
Alumis to Participate in Upcoming February Investor Conferences - The Manila Times
Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Alumis and ACELYRIN announce merger in all-stock deal - MSN
Alumis (NASDAQ:ALMS) Stock Price Up 9.8%What's Next? - MarketBeat
Alumis Inc stock (ALMS) jumps again on Nasdaq — here’s what’s driving the move and what comes next - TechStock²
Why Alumis Inc. Stock Is Suddenly Powering Higher - TipRanks
Chardan highlights Alumis’s (ALMS) potential after envudeucitinib hits all phase 3 endpoints in psoriasis trials - MSN
Alumis Inc. (ALMS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Top Small Cap Stocks To Watch NowJanuary 6th - MarketBeat
Chardan Highlights Alumis's (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials - Finviz
Chardan Highlights Alumis’s (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials - Insider Monkey
Alumis Inc. (NASDAQ:ALMS) Short Interest Up 93.1% in January - MarketBeat
Alumis stock hits all-time high at 27.28 USD By Investing.com - Investing.com Australia
Alumis Inc. (ALMS) Stock Analysis: A Biotech Contender With A 34.43% Potential Upside - DirectorsTalk Interviews
10 New Stocks on the Rise - Insider Monkey
Alumis (NASDAQ:ALMS) Hits New 12-Month HighStill a Buy? - MarketBeat
Alumis stock hits all-time high at 27.28 USD - Investing.com
Alumis (NASDAQ:ALMS) Trading Up 6.4%Should You Buy? - MarketBeat
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - AOL.com
Alumis (NASDAQ:ALMS) Coverage Initiated by Analysts at Chardan Capital - MarketBeat
Alumis stock reaches all-time high at 25.25 USD By Investing.com - Investing.com Australia
This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Chardan Capital initiates coverage on Alumis stock with Buy rating - Investing.com
Chardan Capital initiates coverage on Alumis stock with Buy rating By Investing.com - Investing.com Nigeria
Profit Recap: Is now the right time to enter ASTCJuly 2025 WrapUp & Technical Confirmation Alerts - baoquankhu1.vn
Trading Recap: Is Alumis Inc gaining market shareJuly 2025 Market Mood & Growth Focused Entry Point Reports - baoquankhu1.vn
Aug Reactions: What is the long term forecast for XPLR Infrastructure LP Limited Partnership stock - baoquankhu1.vn
Alumis stock reaches all-time high at 25.25 USD - Investing.com
Aug Weekly: What’s Enterprise Products Partners L.P. Limited Partnership’s historical returnMarket Activity Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs - 24/7 Wall St.
Alumis (ALMS) Is Up 22.0% After Phase 3 Psoriasis Win And $300 Million Equity Raise - Yahoo Finance
HC Wainwright & Co. hikes Alumis Inc. (ALMS)’s price target to $40 from $20, reiterates buy rating - MSN
Alumis (ALMS) price target increased by 79.14% to 36.28 - MSN
Alumis Inc (ALMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alumis Inc 주식 (ALMS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Foresite Labs, LLC | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Foresite Capital Management VI | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Tananbaum James B. | Director |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| AKKARAJU SRINIVAS | Director |
Dec 05 '25 |
Buy |
9.84 |
186,377 |
1,833,760 |
1,265,253 |
| AKKARAJU SRINIVAS | Director |
Dec 03 '25 |
Buy |
7.75 |
100,000 |
775,000 |
1,012,849 |
| AKKARAJU SRINIVAS | Director |
Dec 02 '25 |
Buy |
7.55 |
96,000 |
724,800 |
912,849 |
| AKKARAJU SRINIVAS | Director |
Dec 04 '25 |
Buy |
8.18 |
66,027 |
540,101 |
1,078,876 |
| AKKARAJU SRINIVAS | Director |
Dec 01 '25 |
Buy |
7.46 |
86,350 |
644,171 |
816,849 |
| AKKARAJU SRINIVAS | Director |
Nov 26 '25 |
Buy |
7.64 |
48,537 |
370,823 |
691,797 |
| AKKARAJU SRINIVAS | Director |
Nov 28 '25 |
Buy |
7.64 |
38,702 |
295,683 |
730,499 |
1.24%
0.19%
자본화:
|
볼륨(24시간):